Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer

Harada, Toshiyuki; Imai, Hisao; Fumita, Soichi; Noriyuki, Toshio; Gamoh, Makio; Okamoto, Masaharu; Akashi, Yusaku; Kizawa, Yoshiyuki; Tokoro, Akihiro

doi:10.1007/s10147-020-01790-y

Cited by 8 publications

(3 citation statements)

References 20 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent recommendations published by the European consensus regarding OIC management suggest that when starting opioid management for pain in the palliative care setting, the physicians should start and continue a prophylactic treatment of laxatives (Farmer et al, 2019). In a recent study, prophylactic laxatives were associated with decreasing OIC incidence among patients with cancer (Harada et al, 2021).…”

Section: Introductionmentioning

confidence: 94%

Constipation Severity and Quality of Life among Patients with Cancer Who Received Prophylactic Laxatives: Quasi-Experimental Study

Ahmad¹,

Alnaeem²

2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Prophylactic laxatives were associated with decreasing the incidence of Opioid-induced constipation among patients with cancer. This study aims to evaluate the effectiveness of early prophylactic laxatives therapy on the severity of constipation and quality of life among patients with cancer receiving opioids. Methods: Using a quasiexperimental design with 64 patients assigned to control group and 66 patients assigned to intervention group. The final sample was composed from 112 patients (57 in control group and 55 in intervention group), who were selected from an oncology clinic. Patients in the intervention group have received prophylactical laxatives The intervention included an oral colonic stimulant laxative (i.e., Bisacodyl, Dose= 3 tab/ day and/or Senna 6.8 mg twice daily) and an oral colonic osmotic laxative (i.e., Lactulose, Dose = 15 ml three times per day). Patients in the control group continue to receive their routine care without laxatives. Results: Patients in the intervention group have reported a significant reduction in the severity of constipation symptoms at eight weeks post the intervention (p < 0.001). Furthermore, the patients in the intervention group have revealed a significant improvement in their quality of life (QoL) (p< 0.001). Conclusions: Patients with cancer need to use the first line of laxatives as prophylactic alongside with opioids to minimize the severity of Opioid-induced constipation symptoms and to enhance the QoL.

show abstract

Section: Introductionmentioning

confidence: 94%

Constipation Severity and Quality of Life among Patients with Cancer Who Received Prophylactic Laxatives: Quasi-Experimental Study

Ahmad¹,

Alnaeem²

2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“… 53 Recent European recommendations for OIC management suggest using laxatives for prophylactic purposes when starting opioid therapy. 10 Harada et al, 54 in a recent study, showed that the prophylactic use of laxatives reduces the incidence of OIC in patients with gastrointestinal cancer.…”

Section: Treatmentmentioning

confidence: 99%

Opioid-induced Constipation: Old and New Concepts in Diagnosis and Treatment

Squeo,

Celiberto,

Ierardi

et al. 2024

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Daily use of opioid analgesics has significantly increased in recent years due to an increasing prevalence of conditions associated with chronic pain. Opioid-induced constipation (OIC) is one of the most common, under-recognized, and under-treated side effects of opioid analgesics. OIC significantly reduces the quality of life by causing psychological distress, lowering work productivity, and increasing access to healthcare facilities. The economic and social burden of OIC led to the development of precise strategies for daily clinical practice. Key aspects are the prevention of constipation through adequate water intake and fiber support, avoidance of sedentariness, and early recognition and treatment of cofactors that could worsen constipation. Recommended first-line therapy includes osmotic (preferably polyethylene glycol) and stimulant laxatives. Peripherally acting µ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, or naldemedine, should be used in patients that have not responded to the first-line treatments. The bowel functional index is the main tool for assessing the severity of OIC and for monitoring the response. The paper discusses the recent literature on the pathophysiology, clinical evaluation, and management of OIC and provides a pragmatic approach for its assessment and treatment.

show abstract

“…The use of opioid is known to cause constipation in HSCT patients[ 72 ]. Constipation is thought to be caused by opioids that can cause constipation by different mechanisms, such as increased fluid absorption and inhibition of gastrointestinal secretions.…”

Section: Nutritional Approach In Special Complicationsmentioning

confidence: 99%

Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update

Akbulut

Yeşildemir

2021

WJSC

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) is caused by the newly discovered SARS-CoV-2. Hematopoietic stem cell transplantation (HSCT) is a high-risk procedure. The novelty of COVID-19 has created more uncertainty during all phases of HSCT. It is thought that HSCT patients taking immunosuppressive agents are more likely to contract COVID-19 than healthy individuals are. Appropriate care precautions should be taken with patients undergoing HSCT to minimize the risk of COVID-19, and appropriate treatment methods must be followed in patients infected with COVID-19. Malnutrition has become a significant problem in HSCT patients during the COVID-19 pandemic. The causes of malnutrition in HSCT patients are multifactorial. However, the most important reason is the decrease in energy and nutrient intake. The HSCT procedure can lead to many complications such as dysgeusia, mucositis, diarrhea, constipation, xerostomia and vomiting/nausea. Improving the nutritional status of HSCT patients by managing each of these special complications with an appropriate nutritional approach is essential for successful engraftment. This review aims to provide a comprehensive overview of the specific complications affecting the nutritional status of HSCT patients and their nutritional approach during the challenging COVID-19 pandemic.

show abstract

Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer

Cited by 8 publications

References 20 publications

Constipation Severity and Quality of Life among Patients with Cancer Who Received Prophylactic Laxatives: Quasi-Experimental Study

Constipation Severity and Quality of Life among Patients with Cancer Who Received Prophylactic Laxatives: Quasi-Experimental Study

Opioid-induced Constipation: Old and New Concepts in Diagnosis and Treatment

Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update

Contact Info

Product

Resources

About